118 related articles for article (PubMed ID: 29961573)
1. Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction.
Ueland T; Kleveland O; Michelsen AE; Wiseth R; Damås JK; Holven KB; Aukrust P; Gullestad L; Yndestad A; Halvorsen B
Int J Cardiol; 2019 Jan; 274():348-350. PubMed ID: 29961573
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction.
Kleveland O; Ueland T; Kunszt G; Bratlie M; Yndestad A; Broch K; Holte E; Ryan L; Amundsen BH; Bendz B; Aakhus S; Espevik T; Halvorsen B; Mollnes TE; Wiseth R; Gullestad L; Aukrust P; Damås JK
Int J Cardiol; 2018 Nov; 271():1-7. PubMed ID: 29961572
[TBL] [Abstract][Full Text] [Related]
3. IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction.
Orrem HL; Nilsson PH; Pischke SE; Kleveland O; Yndestad A; Ekholt K; Damås JK; Espevik T; Bendz B; Halvorsen B; Gregersen I; Wiseth R; Andersen GØ; Ueland T; Gullestad L; Aukrust P; Barratt-Due A; Mollnes TE
Front Immunol; 2018; 9():2035. PubMed ID: 30258440
[No Abstract] [Full Text] [Related]
4. Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-Segment-Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform.
George MJ; Kleveland O; Garcia-Hernandez J; Palmen J; Lovering R; Wiseth R; Aukrust P; Engmann J; Damås JK; Hingorani AD; Gullestad L; Casas JP; Ueland T
J Am Heart Assoc; 2020 Jun; 9(12):e015628. PubMed ID: 32515246
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction.
Helseth R; Kleveland O; Ueland T; Wiseth R; Damas JK; Broch K; Michelsen A; Bendz B; Gullestad L; Aukrust P; Seljeflot I
Open Heart; 2021 May; 8(1):. PubMed ID: 33972404
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction.
Holte E; Kleveland O; Ueland T; Kunszt G; Bratlie M; Broch K; Michelsen AE; Bendz B; Amundsen BH; Aakhus S; Damås JK; Gullestad L; Aukrust P; Wiseth R
Heart; 2017 Oct; 103(19):1521-1527. PubMed ID: 28432157
[TBL] [Abstract][Full Text] [Related]
7. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial.
Kleveland O; Kunszt G; Bratlie M; Ueland T; Broch K; Holte E; Michelsen AE; Bendz B; Amundsen BH; Espevik T; Aakhus S; Damås JK; Aukrust P; Wiseth R; Gullestad L
Eur Heart J; 2016 Aug; 37(30):2406-13. PubMed ID: 27161611
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes.
Goldstein SA; Newby LK; Cyr DD; Neely M; Lüscher TF; Brown EB; White HD; Ohman EM; Roe MT; Hamm CW
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28400368
[TBL] [Abstract][Full Text] [Related]
10. Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction.
MBewu AD; Durrington PN; Mackness MI; Hunt L; Turkie WH; Creamer JE
Br Heart J; 1994 Apr; 71(4):316-21. PubMed ID: 8198880
[TBL] [Abstract][Full Text] [Related]
11. A Novel Link Between Adipokines And Lipoprotein (A) To Contemplate Their Diagnostic Role In Patients With Stemi And Nstemi.
Rashid S; Khurshid R; Amir UF; Malik A; Qazi S
J Ayub Med Coll Abbottabad; 2017; 29(1):112-117. PubMed ID: 28712188
[TBL] [Abstract][Full Text] [Related]
12. Peculiarities of heart rate in the patients with unstable angina and non-ST elevation myocardial infarction and concomitant diabetes mellitus type 2.
Hryhoriy K
Wiad Lek; 2016; 69(3 pt 2):524-526. PubMed ID: 27717937
[TBL] [Abstract][Full Text] [Related]
13. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
[TBL] [Abstract][Full Text] [Related]
14. Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin-6 receptor-alpha inhibition with tocilizumab.
Lee JS; Chapman MJ; Piraino P; Lamerz J; Schindler T; Cutler P; Dernick G
Proteomics Clin Appl; 2016 Feb; 10(2):183-94. PubMed ID: 26201085
[TBL] [Abstract][Full Text] [Related]
15. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).
Karsdal MA; Schett G; Emery P; Harari O; Byrjalsen I; Kenwright A; Bay-Jensen AC; Platt A
Semin Arthritis Rheum; 2012 Oct; 42(2):131-9. PubMed ID: 22397953
[TBL] [Abstract][Full Text] [Related]
16. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; Petersen J; Smolen J; Thomson D; Kishimoto T;
Arthritis Rheum; 2006 Sep; 54(9):2817-29. PubMed ID: 16947782
[TBL] [Abstract][Full Text] [Related]
17. ST-segment elevation on intracoronary electrocardiogram after percutaneous coronary intervention is associated with worse outcome in patients with non-ST-segment elevation myocardial infarction.
Hishikari K; Kakuta T; Lee T; Murai T; Yonetsu T; Isobe M
Catheter Cardiovasc Interv; 2016 Mar; 87(4):E113-21. PubMed ID: 26152334
[TBL] [Abstract][Full Text] [Related]
18. Lipoprotein(a) is a risk factor for occurrence of acute myocardial infarction in patients with coronary vasospasm.
Miwa K; Nakagawa K; Yoshida N; Taguchi Y; Inoue H
J Am Coll Cardiol; 2000 Apr; 35(5):1200-5. PubMed ID: 10758961
[TBL] [Abstract][Full Text] [Related]
19. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
